Targeting AURKA in treatment of peritoneal tumor dissemination in gastrointestinal cancer

Hiroki Ozawa, Hiroshi Imazeki, Yamato Ogiwara, Hirofumi Kawakubo, Kazumasa Fukuda, Yuko Kitagawa, Chie Kudo-Saito

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Intraperitoneal (i.p.) tumor dissemination and the consequent malignant ascites remain unpredictable and incurable in patients with gastrointestinal (GI) cancer, and practical advances in diagnosis and treatment are urgently needed in the clinical settings. Here, we explored tumor biological and immunological mechanisms underlying the i.p. tumor progression for establishing more effective treatments. We established mouse tumor ascites models that murine and human colorectal cancer cells were both i.p. and subcutaneously (s.c.) implanted in mice, and analyzed peritoneal exudate cells (PECs) obtained from the mice. We then evaluated anti-tumor efficacy of agents targeting the identified molecular mechanisms using the ascites models. Furthermore, we validated the clinical relevancy of the findings using peritoneal lavage fluids obtained from gastric cancer patients. I.p. tumor cells were giant with large nuclei, and highly express AURKA, but less phosphorylated TP53, as compared to s.c. tumor cells, suggesting polyploidy-like cells. The i.p. tumors impaired phagocytic activity and the consequent T-cell stimulatory activity of CD11b+Gr1+PD1+ myeloid cells by GDF15 that is regulated by AURKA, leading to treatment resistance. Blocking AURKA with MLN8237 or siRNAs, however, abrogated the adverse events, and induced potent anti-tumor immunity in the ascites models. This treatment synergized with anti-PD1 therapy. The CD11b+PD1+ TAMs are also markedly expanded in the PECs of gastric cancer patients. These suggest AURKA is a determinant of treatment resistance of the i.p. tumors. Targeting the AURKA-GDF15 axis could be a promising strategy for improving clinical outcome in the treatment of GI cancer.

Original languageEnglish
Article number101307
JournalTranslational Oncology
Publication statusPublished - 2022 Feb


  • Ascites
  • Gastric cancer
  • Immune checkpoint
  • Peritoneal metastasis
  • Polyploidy
  • Treatment resistance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Targeting AURKA in treatment of peritoneal tumor dissemination in gastrointestinal cancer'. Together they form a unique fingerprint.

Cite this